TY  - GEN
AU  - Schmidt,Charles
TI  - The benefits of immunotherapy combinations
SN  - 1476-4687
PY  - 2018///0517
KW  - Aged
KW  - Antibodies, Monoclonal
KW  - administration & dosage
KW  - Antibodies, Monoclonal, Humanized
KW  - immunology
KW  - Antigens, Neoplasm
KW  - Antineoplastic Agents, Immunological
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - B7-H1 Antigen
KW  - antagonists & inhibitors
KW  - Biomarkers, Tumor
KW  - CTLA-4 Antigen
KW  - Cancer Vaccines
KW  - Cell Cycle Checkpoints
KW  - drug effects
KW  - Clinical Trials as Topic
KW  - Combined Modality Therapy
KW  - Drug Costs
KW  - Humans
KW  - Immunotherapy
KW  - economics
KW  - Indoleamine-Pyrrole 2,3,-Dioxygenase
KW  - Ipilimumab
KW  - Lung Neoplasms
KW  - drug therapy
KW  - Male
KW  - Melanoma
KW  - Nivolumab
KW  - Oncolytic Virotherapy
KW  - Patient Selection
KW  - Precision Medicine
KW  - Programmed Cell Death 1 Receptor
KW  - Survival Analysis
KW  - T-Lymphocytes
KW  - Tryptophan
KW  - analogs & derivatives
KW  - Tumor Escape
N1  - Publication Type: Journal Article
UR  - https://doi.org/10.1038/d41586-017-08702-7
ER  -